Drug profile · INN
dabrafenib mesylate
TAFINLAR
dabrafenib mesylate (TAFINLAR) is a serine/threonine-protein kinase b-raf inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — dabrafenib mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
dabrafenib mesylate (TAFINLAR) is a serine/threonine-protein kinase b-raf inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serine/threonine-protein kinase B-raf inhibitor
Primary target: Serine/threonine-protein kinase B-raf
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is dabrafenib mesylate?
dabrafenib mesylate (TAFINLAR) is a serine/threonine-protein kinase b-raf inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for dabrafenib mesylate?
TAFINLAR is a marketed brand name for dabrafenib mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dabrafenib mesylate?
dabrafenib mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.